

# Xavier Forns

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6313836/xavier-forns-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

303 papers	16,165 citations	60 h-index	121 g-index
353 ext. papers	18,306 ext. citations	5.9 avg, IF	6.23 L-index

#	Paper	IF	Citations
303	Considerations for optimizing Wilson's disease patients' long-term follow-up. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , <b>2022</b> , 45, 146-146	0.1	
302	Primary herpes simplex virus type 1 infection with acute liver failure in solid organ transplantation: Report of three cases and review.. <i>IDCases</i> , <b>2022</b> , 28, e01485	2	0
301	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , <b>2021</b> ,	13.3	9
300	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	1
299	Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination. <i>Journal of Viral Hepatitis</i> , <b>2021</b> ,	3.4	1
298	Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. <i>Nature Communications</i> , <b>2021</b> , 12, 6910	17.4	6
297	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	11
296	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , <b>2021</b> ,	19.2	21
295	Red yeast rice extract: The risky trend of natural products. <i>Gastroenterology &amp; Hepatology</i> , <b>2021</b> , 44, 293-294	0.9	1
294	Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , <b>2021</b> , 10, 1253-1266	6.2	2
293	Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1019-1024	3.4	2
292	Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. <i>Advances in Therapy</i> , <b>2021</b> , 38, 3409-3426	4.1	1
291	Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1331-1332	3.4	
290	Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1064-1074	13.4	15
289	Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 89-94	3.4	32
288	Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. <i>Liver International</i> , <b>2021</b> ,	7.9	1
287	Hepatitis C therapy and anticonvulsants. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , <b>2021</b> , 44, 536	0.1	

286	Hepatitis C therapy and anticonvulsants. <i>Gastroenterología Y Hepatología</i> , <b>2021</b> , 44, 536	0.9	
285	Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. <i>Liver International</i> , <b>2021</b> , 41, 2733-2746	7.9	0
284	Externalized HCV linkage-to-care cascade in the biggest harm reduction center in Barcelona: approaching a high-risk PWID population. <i>Journal of Hepatology</i> , <b>2020</b> , 73, S360	13.4	3
283	Liver transplant immunosuppression during the covid-19 pandemic. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 457-463	0.9	12
282	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1415-1424	13.4	55
281	Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 129	8.4	4
280	Complete Remission of Hypertrophic Discoid Cutaneous Lupus Erythematosus After Treatment of Chronic Hepatitis C With Direct-Acting Antivirals. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 471-472	5.1	3
279	Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 389-394	2.2	0
278	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2020</b> , 43, 14-21	0.1	
277	Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1570-1578	4	7
276	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 14-21	0.9	1
275	The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy. <i>Gastroenterología Y Hepatología</i> , <b>2020</b> , 43, 136-137	0.9	1
274	The HBeAg-Negative "Gray Zone" Phase: A Frequent Condition With Different Outcomes in Western and Asian Patients?. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 263-264	6.9	1
273	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , <b>2020</b> , 174, 104694	10.8	20
272	Low seroprevalence and zero incidence rate of hepatitis E in men who have sex with men during a hepatitis A outbreak. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 1359-1362	19.7	2
271	Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodies. <i>Liver International</i> , <b>2020</b> , 40, 558-564	7.9	8
270	Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut". <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1036-1037	13.4	1
269	Improvement of sexuality after hepatitis C cure with direct acting antivirals. <i>Liver International</i> , <b>2020</b> , 40, 2972-2977	7.9	2

268	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1360-1367	13.4	7
267	SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1262-1263	13.4	12
266	Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8 T cells after direct-acting antiviral therapies. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1408-1418	3.4	2
265	Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	27
264	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 472-480	13.4	79
263	Incidence of depression in patients with hepatitis C treated with direct-acting antivirals. <i>Revista Brasileira De Psiquiatria</i> , <b>2020</b> , 42, 72-76	2.6	8
262	Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 968-973	6.1	2
261	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 874-884	13.4	44
260	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". <i>Journal of Hepatology</i> , <b>2019</b> , 71, 447-448	13.4	124
259	Association of chronic inflammation and perceived stress with abnormal functional connectivity in brain areas involved with interoception in hepatitis C patients. <i>Brain, Behavior, and Immunity</i> , <b>2019</b> , 80, 204-218	16.6	4
258	Fanconi syndrome due to tenofovir disoproxil fumarate (TDF) after liver transplantation. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1352-1353	3.3	3
257	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2019</b> , 42, 579-592	0.1	2
256	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2019</b> , 111, 862-873	0.9	4
255	Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation. <i>Journal of General Virology</i> , <b>2019</b> , 100, 63-68	4.9	0
254	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42, 579-592	0.9	13
253	Contributing awareness of autoimmune hepatitis in HIV patients. <i>Aids</i> , <b>2019</b> , 33, 2103-2105	3.5	
252	Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 875-881	3.3	
251	Severe hepatitis B reactivation during direct-acting antiviral treatment in "the absence" of hepatitis B surface antigen. <i>International Journal of Infectious Diseases</i> , <b>2019</b> , 79, 47-49	10.5	4

250	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. <i>Liver International</i> , <b>2019</b> , 39, 826-834	7.9	11
249	The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 11-17	13.4	54
248	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , <b>2018</b> , 68, 1298-1307	11.2	121
247	Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1397-1408	6.1	19
246	Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus. <i>Liver Transplantation</i> , <b>2018</b> , 24, 703-707	4.5	5
245	Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 940-948	13.4	12
244	Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations". <i>Journal of Hepatology</i> , <b>2018</b> , 68, 627-628	13.4	
243	Massive hemolysis complicating acute granulomatous hepatitis. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1741-1742		
242	Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. <i>Liver International</i> , <b>2018</b> , 38, 1940-1950	7.9	10
241	Systematic review with meta-analysis: neuroimaging in hepatitis C chronic infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1238-1252	6.1	7
240	Reply. <i>Gastroenterology</i> , <b>2018</b> , 154, 1551-1552	13.3	
239	Hepatitis A outbreak in Barcelona among men who have sex with men (MSM), January-June 2017: A hospital perspective. <i>Liver International</i> , <b>2018</b> , 38, 588-593	7.9	25
238	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. <i>Hepatology</i> , <b>2018</b> , 67, 1683-1694	11.2	83
237	Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. <i>Gastroenterology</i> , <b>2018</b> , 155, 311-315.e6	13.3	51
236	An uncommon presentation of alcoholic liver disease. <i>Liver International</i> , <b>2018</b> , 38, 1514	7.9	
235	Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction?. <i>Current Hepatology Reports</i> , <b>2018</b> , 17, 209-217	1	4
234	Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 1515-1525	3.4	7
233	Treatment of chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 544-546	13.4	3

232	Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 603-607	13.4	44
231	Severe Hepatitis C Recurrence as a Risk Factor for Opportunistic Infections in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , <b>2018</b> , 50, 1437-1443	1.1	2
230	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 597-608	0.9	10
229	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 597-608	0.1	
228	Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1007284	7.6	10
227	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , <b>2018</b> , 155, 1120-1127.e4	13.3	47
226	Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1156-1161	6.1	39
225	Juan Rod�, M.D., Ph.D. (1938-2017): Excellence and leadership. <i>Hepatology</i> , <b>2017</b> , 65, 2137-2138	11.2	
224	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , <b>2017</b> , 37, 1823-1832	7.9	8
223	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 494-500	18.8	37
222	Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1559-1560	6.1	1
221	Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing. <i>Journal of Clinical Virology</i> , <b>2017</b> , 92, 42-47	14.5	13
220	Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1400-1409	0.7	20
219	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , <b>2017</b> , 37, 109-118	7.3	59
218	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 823-831	3.4	80
217	Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. <i>Transplant Infectious Disease</i> , <b>2017</b> , 19, e12696	2.7	10
216	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 718-723	13.4	80
215	Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Annals of Hematology</i> , <b>2017</b> , 96, 405-410	3	11

214	Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1168-1176	13.4	77
213	A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. <i>Scientific Reports</i> , <b>2017</b> , 7, 10497	4.9	16
212	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , <b>2017</b> , 153, 1273-1283.e1	13.3	164
211	Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. <i>Virus Research</i> , <b>2017</b> , 240, 35-46	6.4	2
210	Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. <i>Lancet Infectious Diseases</i> , <b>2017</b> , 17, 1062-1068	25.5	238
209	Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection - Authors' reply. <i>Lancet Infectious Diseases</i> , <b>2017</b> , 17, 1240	25.5	
208	MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1b infection. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S90-S91	13.4	47
207	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 575-583.e1	6.9	75
206	Hepatitis B Reactivation or Hepatitis C Exacerbation in Patients with Hematological Malignancies. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 179-181	3.1	1
205	Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. <i>Annals of Hepatology</i> , <b>2017</b> , 16, 312-317	3.1	3
204	Extrahepatic Manifestations in Patients With Chronic Hepatitis C Virus Infection. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 13, 173-202	0.3	
203	Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. <i>Revista Española De Sanidad Penitenciaria</i> , <b>2017</b> , 19, 87-97	0.4	9
202	Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 32-6	11.6	85
201	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , <b>2016</b> , 65, 864-865	13.4	6
200	Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation. <i>Liver Transplantation</i> , <b>2016</b> , 22, 298-304	4.5	25
199	Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 364-74	6.1	12
198	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 685-697	25.5	346
197	Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. <i>PLoS ONE</i> , <b>2016</b> , 11, e0145409	3.7	5

196	Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166631	3.7	4
195	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168544	3.7	1
194	Early non-invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation. <i>Transplant Infectious Disease</i> , <b>2016</b> , 18, 471-9	2.7	11
193	Simple prediction of long-term clinical outcomes in patients with mild hepatitis C recurrence after liver transplantation. <i>Transplant International</i> , <b>2016</b> , 29, 698-706	3	4
192	Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. <i>Gastroenterology</i> , <b>2016</b> , 151, 633-636.e3	13.3	15
191	Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1662-1666.e1	6.9	34
190	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 719-726	13.4	709
189	Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 845-51	0.7	10
188	Challenges in Special Populations: HIV/HCV Coinfection, Liver Transplantation and Patients with End-Stage Renal Disease. <i>Digestive Diseases</i> , <b>2016</b> , 34, 317-26	3.2	9
187	Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. <i>Annals of Hepatology</i> , <b>2016</b> , 15, 512-23	3.1	1
186	Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. <i>Hepatology</i> , <b>2015</b> , 61, 1485-94	11.2	183
185	G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S187-S188	13.4	53
184	LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S269-S270	13.4	21
183	LP24 : Safety, efficacy and impact on liver function of simeprevir (SMV) in combination with daclatasvir (DCV) or sofosbuvir (SOF) in patients with severe hepatitis C recurrence after liver transplantation (LT): results from compassionate use in europe. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S275-S276	13.4	4
182	P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S620-S621	13.4	13
181	P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S623	13.4	6
180	O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S190	13.4	23
179	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , <b>2015</b> , 68, 56-60	14.5	9

178	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 753-62	13.4	3
177	Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 564-72	13.4	123
176	Therapy. Statins and liver disease: from concern to 'wonder' drugs?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2015</b> , 12, 320-1	24.2	14
175	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1846-1853.e1	6.9	45
174	Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. <i>Genes and Immunity</i> , <b>2015</b> , 16, 297-300	4.4	8
173	Advances in hepatitis C therapies. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1929-43	4	2
172	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. <i>Liver International</i> , <b>2015</b> , 35, 2358-62	7.9	14
171	Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1535-6	13.4	3
170	How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 250	5.7	24
169	Hepatitis C virus infection inhibits P-body granule formation in human livers. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 785-90	13.4	9
168	Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. <i>Gastroenterology</i> , <b>2015</b> , 148, 108-17	13.3	280
167	High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 219-26	9.7	64
166	Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 366-75	3.4	13
165	Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. <i>Gastroenterology</i> , <b>2015</b> , 148, 100-107.e1	13.3	266
164	Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRW12 analysis. <i>Liver International</i> , <b>2015</b> , 35, 90-100	7.9	12
163	Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 469-80	3.4	6
162	Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 149-55	1.6	11
161	Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. <i>Transplant International</i> , <b>2015</b> , 28, 1345-9	3	15

160	Hepatitis C treatment for patients post liver transplant. <i>Current Opinion in Organ Transplantation</i> , <b>2015</b> , 20, 251-8	2.5	3
159	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 5421-6	5.6	5
158	Chronic hepatitis C, depression and gender: a state of art. <i>Advances in Dual Diagnosis</i> , <b>2015</b> , 8, 193-210	1.1	3
157	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 311-6	13.4	11
156	Clinical trial watch: reports from the AASLD Liver Meeting, Boston, November 2014. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1196-203	13.4	18
155	HEV infection in two referral centers in Spain: epidemiology and clinical outcomes. <i>Journal of Clinical Virology</i> , <b>2015</b> , 63, 76-80	14.5	19
154	Quasispecies dynamics in hepatitis C liver transplant recipients receiving grafts from hepatitis C virus infected donors. <i>Journal of General Virology</i> , <b>2015</b> , 96, 3493-3498	4.9	8
153	Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C. <i>American Journal of Transplantation</i> , <b>2014</b> , 14, 375-83	8.7	39
152	ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1973-82	59.2	754
151	Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" Conditions. <i>Value in Health</i> , <b>2014</b> , 17, A367	3.3	
150	Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3451-60	5.9	15
149	IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. <i>Journal of Clinical Virology</i> , <b>2014</b> , 61, 282-5	14.5	3
148	New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. <i>Gut</i> , <b>2014</b> , 63, 207-15	19.2	26
147	P219 FINE MAPPING OF THE BUTYROPHILIN GENOMICS REGION: ROLE IN HEPATITIS C VIRUS INFECTION (HCV). <i>Journal of Hepatology</i> , <b>2014</b> , 60, S139	13.4	2
146	P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S499	13.4	20
145	O163 TURQUOISE-II: SVR12 RATES OF 92.6% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV). <i>Journal of Hepatology</i> , <b>2014</b> , 60, S523	13.4	4
144	Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. <i>Gastroenterology</i> , <b>2014</b> , 146, 1669-79.e3	13.3	214
143	O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S28	13.4	47

142	O114 RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S47	13.4	19
141	THU0298 Are Anti-La Antibodies A Potential Protection for Hepatitis C Virus Infection in Sjögren Syndrome? Analysis in 663 Patients. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 286.2-286	2.4	
140	Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen $\alpha$ chain precedes fibrosis progression in patients with liver disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e109254	3.7	12
139	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 356-363	3.1	15
138	Interferon-free regimens in the liver-transplant setting. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 58-71	7.3	31
137	Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46 Suppl 5, S197-205	3.3	6
136	Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. <i>Journal of Virology</i> , <b>2014</b> , 88, 667-78	6.6	2
135	An interferon-free antiviral regimen for HCV after liver transplantation. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 2375-82	59.2	335
134	Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. <i>Journal of Hepatology</i> , <b>2014</b> , 61, S120-31	13.4	57
133	Graft and viral outcomes in retransplantation for hepatitis C virus recurrence and HCV primary liver transplantation: a case-control study. <i>Clinical Transplantation</i> , <b>2014</b> , 28, 821-8	3.8	7
132	Viral hepatitis and liver transplantation: pathogenesis, prevention and therapy of recurrent disease. <i>Digestive Diseases</i> , <b>2014</b> , 32, 538-44	3.2	3
131	HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 242ra81	17.5	60
130	Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 270-7	13.4	11
129	P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S481	13.4	11
128	O62 SOFOSBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S26	13.4	21
127	Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e1113-21	4.6	30
126	Treatment of Hepatitis C Before Liver Transplantation <b>2014</b> , 1-14		
125	Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. <i>Journal of Gastroenterology</i> , <b>2013</b> , 48, 762-9	6.9	17

124	Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. <i>Hepatology</i> , <b>2013</b> , 58, 1587-97	11.2	33
123	Imaging of hepatitis C virus infection in liver grafts after liver transplantation. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 271-8	13.4	8
122	Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 415-20	13.4	37
121	Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors. <i>Current Opinion in Organ Transplantation</i> , <b>2013</b> , 18, 271-8	2.5	4
120	P14: HepatiC, the viral hepatitis C patients management application and database. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 23-24	3.4	
119	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. <i>Liver Transplantation</i> , <b>2013</b> , 19, 450-6	4.5	7
118	Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. <i>Medicine (United States)</i> , <b>2013</b> , 92, 273-284	1.8	53
117	Reply: To PMID 21294144. <i>Hepatology</i> , <b>2013</b> , 57, 855	11.2	
116	A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19 Suppl 2, 1-26	3.4	60
115	Insulin resistance and response to telaprevir plus peginterferon and ribavirin in treatment-naïve patients infected with HCV genotype 1. <i>Gut</i> , <b>2012</b> , 61, 1473-80	19.2	61
114	Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 355-8	13.4	14
113	Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 213-4	13.4	5
112	ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 281-7	13.4	123
111	Viral hepatitis in liver transplantation. <i>Gastroenterology</i> , <b>2012</b> , 142, 1373-1383.e1	13.3	156
110	Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. <i>PLoS ONE</i> , <b>2012</b> , 7, e47715	3.7	48
109	Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. <i>PLoS ONE</i> , <b>2012</b> , 7, e52651	3.7	16
108	A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus. <i>PLoS ONE</i> , <b>2012</b> , 7, e53254	3.7	6
107	Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. <i>Journal of Clinical Psychiatry</i> , <b>2012</b> , 73, 1128-38	4.6	216

106 Assessing the Progression of Chronic HCV to Cirrhosis **2012**, 21-33

105	Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. <i>Gastroenterology</i> , <b>2011</b> , 140, 459-468.e1; quiz e14	13.3	111
104	Cell culture replication of a genotype 1b hepatitis C virus isolate cloned from a patient who underwent liver transplantation. <i>PLoS ONE</i> , <b>2011</b> , 6, e23587	3.7	11
103	Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2011</b> , 23, 942-7	2.2	5
102	Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 138-48	6.1	71
101	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , <b>2011</b> , 31 Suppl 2, 30-60	7.9	293
100	Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting. <i>American Journal of Transplantation</i> , <b>2011</b> , 11, 767-74	8.7	9
99	Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. <i>American Journal of Transplantation</i> , <b>2011</b> , 11, 1051-7	8.7	71
98	Noninvasive assessment of liver fibrosis. <i>Hepatology</i> , <b>2011</b> , 53, 325-35	11.2	278
97	Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. <i>Hepatology</i> , <b>2011</b> , 53, 1436-45	11.2	29
96	Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. <i>Medicine (United States)</i> , <b>2011</b> , 90, 359-371	1.8	203
95	Primary Sjögren's Syndrome and Viruses <b>2011</b> , 55-66		
94	Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. <i>Gastroenterology</i> , <b>2010</b> , 138, 147-58.e1	13.3	56
93	Retransplantation in patients with hepatitis C recurrence after liver transplantation. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 962-70	13.4	52
92	Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 2164-72; quiz 2173	0.7	53
91	Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. <i>Hepatology</i> , <b>2010</b> , 51, 23-34	11.2	103
90	Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. <i>Hepatology</i> , <b>2010</b> , 51, 974-85	11.2	114
89	Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. <i>Journal of General Virology</i> , <b>2010</b> , 91, 1183-8	4.9	31

88	Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. <i>American Journal of Physiology - Renal Physiology</i> , <b>2009</b> , 297, G726-34	5.1	95
87	Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. <i>American Journal of Transplantation</i> , <b>2009</b> , 9, 1591-601	8.7	45
86	Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1442-8	4.1	107
85	Role of nosocomial hospital transmission in acute hepatitis C: Reply. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 214	13.4	
84	Interpreting liver stiffness in the cirrhotic range: What are we measuring?. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 424-425	13.4	2
83	Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 719-28	13.4	167
82	Antiviral therapy in HCV-infected cirrhotic patients awaiting liver transplantation. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 960-962	13.4	0
81	Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, e4-7	3.3	12
80	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 23-32	1.6	50
79	Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 20-7	13.4	362
78	Non-invasive evaluation of liver fibrosis using transient elastography. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 835-47	13.4	964
77	Nosocomial acquisition of the hepatitis C virus. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 1020-1021	13.4	3
76	MR elastography to assess liver fibrosis. <i>Radiology</i> , <b>2008</b> , 247, 591; author reply 591-2	20.5	9
75	Virology and pathogenesis of hepatitis C virus recurrence. <i>Liver Transplantation</i> , <b>2008</b> , 14 Suppl 2, S27-35	4.5	44
74	Cirrosis por el virus de la hepatitis C <b>2008</b> , 357-368		
73	Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. <i>Gastroenterology</i> , <b>2007</b> , 132, 1746-56	13.3	299
72	Noninvasive tests in the postliver transplantation setting. <i>Liver Transplantation</i> , <b>2007</b> , 13, 628-629	4.5	1
71	Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. <i>Journal of Viral Hepatitis</i> , <b>2007</b> , 14, 736-42	3.4	20

70	Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. <i>American Journal of Transplantation</i> , <b>2007</b> , 7, 2172-9	8.7	8
69	Antiviral therapy in HCV decompensated cirrhosis: to treat or not to treat?. <i>Journal of Hepatology</i> , <b>2007</b> , 46, 185-8	13.4	11
68	[33] HEPATITIS C VIRUS COMPARTMENTALIZATION AND INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , <b>2007</b> , 46, S16	13.4	2
67	Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 36, 189-96	5.3	78
66	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , <b>2006</b> , 43, 72-80	11.2	41
65	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. <i>Hepatology</i> , <b>2006</b> , 43, 492-9	11.2	238
64	Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , <b>2006</b> , 12, 1791-8	4.5	315
63	Tratamiento de mantenimiento. <i>Gastroenterología Y Hepatología</i> , <b>2006</b> , 29, 180-183	0.9	
62	HCV virological assessment. <i>Journal of Hepatology</i> , <b>2006</b> , 44, S35-9	13.4	20
61	The extrahepatic contribution to HCV plasma viremia. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 626-7; author reply 627-8	13.4	7
60	Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 544-51	3.4	13
59	Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061. <i>Antiviral Therapy</i> , <b>2006</b> , 11, 371-376	1.6	18
58	Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 491-8	13.4	61
57	Performance of hepatitis C virus core antigen immunoassay in monitoring viral load after liver transplantation. <i>Transplantation</i> , <b>2005</b> , 79, 1441-4	1.8	6
56	Nosocomial transmission of HCV in the liver unit of a tertiary care center. <i>Hepatology</i> , <b>2005</b> , 41, 115-22	11.2	45
55	Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. <i>Journal of General Virology</i> , <b>2005</b> , 86, 1067-1075	4.9	55
54	Treatment of HCV infection in patients with advanced cirrhosis. <i>Hepatology</i> , <b>2004</b> , 40, 498	11.2	17
53	Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. <i>Hepatology</i> , <b>2004</b> , 40, 699-707	11.2	158

52	Evolution of hepatitis C virus quasispecies immediately following liver transplantation. <i>Liver Transplantation</i> , <b>2004</b> , 10, 1131-9	4.5	48
51	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. <i>Gastroenterology</i> , <b>2004</b> , 127, 1347-55	13.3	284
50	Prevention and treatment of hepatitis C virus recurrence after liver transplantation. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 2-10	13.4	32
49	Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. <i>Transplantation</i> , <b>2004</b> , 78, 686-91	1.8	68
48	Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. <i>Medicine (United States)</i> , <b>2003</b> , 82, 87-96	1.8	76
47	Can we identify liver fibrosis in HCV-infected patients without a liver biopsy?. <i>Current Hepatitis Reports</i> , <b>2003</b> , 2, 145-151		4
46	Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 389-96	13.4	248
45	Expected developments in hepatology. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2002</b> , 16, 957-70	2.5	5
44	Hepatitis C virus kinetics during and immediately after liver transplantation. <i>Hepatology</i> , <b>2002</b> , 35, 680-711.2	11.2	411
43	Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. <i>Hepatology</i> , <b>2002</b> , 36, 986-92	11.2	753
42	The challenge of developing a vaccine against hepatitis C virus. <i>Journal of Hepatology</i> , <b>2002</b> , 37, 684-95	13.4	58
41	DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. <i>Vaccine</i> , <b>2002</b> , 20, 3263-71	4.1	33
40	Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. <i>Hepatology</i> , <b>2002</b> , 36, 986-992	11.2	17
39	Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. <i>Intervirology</i> , <b>2001</b> , 44, 132-42	2.5	49
38	Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. <i>Journal of Medical Virology</i> , <b>2001</b> , 65, 35-44	19.7	22
37	High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. <i>Hepatology</i> , <b>2001</b> , 34, 158-67	11.2	38
36	Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. <i>Journal of Hepatology</i> , <b>2001</b> , 35, 265-71	13.4	43
35	Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C <b>2001</b> , 65, 35		2

34	Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. <i>Journal of Medical Virology</i> , <b>2001</b> , 65, 35-44	19.7	14
33	Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. <i>Virology</i> , <b>2000</b> , 274, 75-85	3.6	34
32	Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. <i>Virology</i> , <b>2000</b> , 277, 358-67	3.6	43
31	Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. <i>Hepatology</i> , <b>2000</b> , 32, 618-25	11.2	126
30	Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2000</b> , 97, 13318-23	11.5	127
29	Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2000</b> , 33, 135-41	13.4	14
28	Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum. <i>Journal of Medical Virology</i> , <b>1999</b> , 58, 35-43	19.7	14
27	High prevalence of TT virus (TTV) infection in patients on maintenance hemodialysis: Frequent mixed infections with different genotypes and lack of evidence of associated liver disease. <i>Journal of Medical Virology</i> , <b>1999</b> , 59, 313-317	19.7	45
26	Quasispecies in viral persistence and pathogenesis of hepatitis C virus. <i>Trends in Microbiology</i> , <b>1999</b> , 7, 402-10	12.4	112
25	DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. <i>Vaccine</i> , <b>1999</b> , 17, 1992-2002	4.1	47
24	Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 1028-34	13.4	59
23	The molecular biology of hepatitis C virus. Genotypes and quasispecies. <i>Clinics in Liver Disease</i> , <b>1999</b> , 3, 693-716, vii	4.6	67
22	The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 839-47	7	101
21	Hepatitis G virus infection in chronic liver disease. <i>Gut</i> , <b>1998</b> , 42, 107-11	19.2	32
20	Hepatitis G virus infection in fulminant hepatic failure. <i>Gut</i> , <b>1997</b> , 41, 696-9	19.2	21
19	Incidence and risk factors of hepatitis C virus infection in a haemodialysis unit. <i>Nephrology Dialysis Transplantation</i> , <b>1997</b> , 12, 736-40	4.3	42
18	Hepatitis G virus infection in a haemodialysis unit: prevalence and clinical implications. <i>Nephrology Dialysis Transplantation</i> , <b>1997</b> , 12, 956-60	4.3	35
17	Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>1997</b> , 27, 959-65	13.4	107

16	Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapy. <i>Journal of Hepatology</i> , <b>1997</b> , 26, 787-93	13.4	44
15	How <i>Escherichia coli</i> can bias the results of molecular cloning: preferential selection of defective genomes of hepatitis C virus during the cloning procedure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 13909-14	11.5	52
14	Evaluation of commercially available and in-house reverse transcription-PCR assays for detection of hepatitis G virus or GB virus C. <i>Journal of Clinical Microbiology</i> , <b>1997</b> , 35, 2698-702	9.7	7
13	Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrhosis after liver transplantation. <i>Journal of Hepatology</i> , <b>1996</b> , 25, 129-34	13.4	46
12	Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. <i>Journal of Hepatology</i> , <b>1996</b> , 25, 827-32	13.4	38
11	Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial. <i>Gut</i> , <b>1996</b> , 38, 603-9	19.2	10
10	Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. <i>Journal of Clinical Microbiology</i> , <b>1996</b> , 34, 2516-21	9.7	43
9	Value of duplex-doppler ultrasound findings in liver transplant recipients with poor graft function. <i>Transplantation</i> , <b>1996</b> , 61, 832-5	1.8	7
8	Management of ascites and renal failure in cirrhosis. <i>Seminars in Liver Disease</i> , <b>1994</b> , 14, 82-96	7.3	36
7	Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. <i>Hepatology</i> , <b>1994</b> , 20, 1495-501	11.2	413
6	Disulfiram-induced hepatitis. Report of four cases and review of the literature. <i>Journal of Hepatology</i> , <b>1994</b> , 21, 853-7	13.4	51
5	Amyotrophic lateral sclerosis in a patient with systemic lupus erythematosus. <i>Lupus</i> , <b>1993</b> , 2, 133-4	2.6	9
4	Development of amyotrophic lateral sclerosis in the course of systemic lupus erythematosus. <i>Clinical Rheumatology</i> , <b>1992</b> , 11, 578-9	3.9	2
3	Genotypes 2 and 3 Relapse and Non-Response104-112		
2	Chronic viral hepatitis C610-617		
1	Recurrent Disease and Management in Liver Transplantation2010-2018		